Neurologist Christoph Diener discusses the evidence to date on GLP-1 receptor agonists in stroke, addiction, Parkinson's disease, and beyond.
Professor, Department of Neurology, Stroke Center-Headache Center, University Duisburg-Essen, Essen, Germany
Dear colleagues, I am Christoph Diener, from the Faculty of Medicine at the University of Duisburg-Essen in Germany. I usually report five or six studies in the field of neurology that were published in the last months, but July obviously was a vacation month.-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonists beyond diabetes and obesity, and in particular, for the field of neurology and psychiatry.
We have a number of preclinical models, mostly in transgenic mice, which show that these drugs are not only effective in diabetes and obesity, but also in liver disease, kidney failure, and neurodegenerative diseases. GLP-1 receptor agonists also have powerful anti-inflammatory properties. These drugs reduce body weight, and they have positive effects on blood pressure and lipid metabolism.
In the therapy studies on diabetes and obesity, there were indications that some smokers in the studies stopped their nicotine consumption. Ain 84 overweight patients who were smokers showed that 46% of patients on exenatide stopped smoking compared with 27% in the placebo group. This could be an indication that GLP-1 receptor agonists have activity on the reward system in the brain. Currently, there are a number of larger placebo-controlled trials ongoing.
The most important limitation at the moment beyond the cost is the other adverse drug reactions with the GLP-1 receptor agonists; these include nausea, vomiting,. There might be a slightly increased risk for pancreatitis. The US Food and Drug Administration recently reported there is no increased risk forThese drugs, GLP-1 receptor agonists and GIP agonists, are also investigated in a variety of other non-neurologic diseases.
Obese GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Alcohol Abuse Hypertension Parkinson's Disease Parkinson Disease Parkinsons Parkinson Parkinson Disease (PD) Stroke Cerebrovascular Accident CVA - Cerebrovascular Accident Fellowship Fellows Residency Residents
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New in Neurology: Colchicine, GLP-1s, and Physiotherapy vs Psychotherapy in Motor DisordersProf Christoph Diener discusses recent neurology updates in stroke care, sleep apnea, antipsychotics and dementia, and how to best treat motor disorders.
Read more »
Secrets of a Neurology Whisperer: Talk Less, Teach MoreA diminished voice and potential health scare taught this neurologist that maybe less is more when it comes to teaching medical students and residents.
Read more »
Jersey's neurology department set for review amid 'concerns'The review is part of a plan listing 60 ways Jersey's health service can be improved.
Read more »
Diabetes patients now have access to first generic GLP-1 medication: ‘More accessible and affordable’The first-ever generic GLP-1 medication — a duplicate version of Teva Pharmaceuticals' Victoza — was launched on June 25. Doctors explain the potential benefits for diabetes patients.
Read more »
Promising New Data Support GLP-1s for Dementia PreventionNew clinical trial data suggest promising therapeutic effects of the GLP-1 liraglutide on cognition and brain size in individuals with Alzheimer's disease.
Read more »
Healthy Returns: Here's what GLP-1s are being tested for beyond weight loss, diabetesThe list of potential health benefits from GLP-1 is only getting longer. Meanwhile, the heads of Commure, Augmedix share details about an acquisition.
Read more »